1 The selectivity of action of boldine and the related aporphine alkaloids, predicen trine (9-0-methylboldine) and glaucine (2,9-0-dimethylboldine) on (X¡-adrenoceptor subtypes was studied by examining pH]-prazosin competition binding in rat cerebral cortex. WB 4101 and benoxathian were used as selective (X¡A-adrenoceptorantagonists. 2 In the competition experiments pH]-prazosin (0.2 nM) binding was inhibited by WB 4101 and benoxathian. The inhibition curves displayed shallow slopes which could be subdivided into high and low affinity components with a single pK¡ value (7.76). 5 These results suggest that whereas the aporphine structure shared by these alkaloids is responsible for their selectivity of action for the (X¡A-adrenoceptor subtype in rat cerebral cortex, defined functional groups, namely the 2-hydroxy function, induces a significant increase in (X¡A-subtypeselectivity and affinity.
Introduction
Papaverine, a benzylisoquinoline alkaloid, is a well-known spasmolytic agent that acts by a non-specific inhibition of cyclic nucleotide phosphodiesterases (PDEs) (Lugnier el al., 1972; Bolton, 1979; Cumiskey & Feigenson, 1983; Ivorra el al., 1992) ; but there is also evidence that it may antagonize Ca2+ 'influx (Reinhardt el al., 1977) and act on (X¡-adrenoceptors (O'Hara & Ono, 1986; Ivorra el al., 1992) . In previous work we have shown that a series of benzylisoquinoline derivative alkaloids, structurally related to papaverine, have a relaxant effect on the vascular smooth muscle that is also related to their capacity to inhibit Ca2+ influx through voltage-operated Ca2+ channels, act as (X¡-adrenoceptor antagonists and inhibit all or some of the different forms of PDEs isolated from aorta (Ivorra el al., 1992; Chuliá el al., 1994) . The importance of the results obtained residues in the fact that small changes in the structure of papaverine lead to compounds with a selective action for one or another of the above mentioned mechanisms. It thus seems that compounds with a tetrahydroisoquinoline ring, instead of the isoquinoline ring present in papaverine, act mainly at (X¡-adrenoceptors. This is the case for laudanosine, a benzyltetrahydroisoquinoline alkaloid (Chuliá el al., 1994) , and for some aporphine structures such as glaucine, boldine and apomorphine (Ivorra el al., 1992; . This more specific action on (Xl-adrenoceptors was accompanied by a loss in the activity of these alkaloids as PDEs inhibitors. Radioligand binding studies have shown that, of these compounds, boldine is the most IAuthor for correspondence potent in inhibiting [3H]-prazosin binding to rat cortical cerebral membranes, and it seems to exhibit a complex interaction at (X¡-adrenoceptors that suggests the presence of more than a single class of binding site (Ivorra el al., 1993) .
As (X¡-adrenoceptors are not homogeneous and several subtypes have been described (for review see Ford el al., 1994; Hieble el al., 1995; Michel el al., 1995) , the above observations prompted us to study the possible subtype selectivity of boldine ( Figure 1 ) for (X¡-adrenoceptor subtypes present in rat cerebral cortex. In order to explore some structural requirements of (X¡-adrenoceptor selectivity, we also studied the effects of two other aporphines, predicentrine (9-0-methylboldine) and glaucine (2,9-0-dimethylboldine), differing from boldine only by the methylation of one or both phenolic hydroxyl groups (Figure 1 ). WB4101 and benoxathian were used as selective (X¡A-adrenoceptorantagonists. The affinities of different compounds for the (XlA-and (X¡B-adrenoceptorsubtypes were evaluated by studying their ability to displace specific [3H]_ prazosin binding from rat cerebral cortex membranes.
Methods

Binding sludy Preparalion o/ membranes
Female Wistar rats (180-200 g) were decapitated and the brain was rapidly removed. The cerebral cortex was homogenized in 10 vol.(w/v) of ice-cold buffer (Tris HCl5 mM, sucrose 250 mM and EDTA 1 mM, pH 7.5 at 25°C) using an ultra-turrax (two, 15 s). The homogenate was centrifuged for 10 min at 1000 g. The pellet was discarded and the supernatant was centrifuged at 50,000 g for 15 min at 4°C. The pellet was resuspended in the same volume of assay buffer (Tris HCI 50 mM, pH 7.5) and centrifuged at 50,000 g for 15 min at 4°C. The final pellet was resuspended in assay buffer and stored at -70°C for later use. All procedures to prepare membranes were conducted at 4°C.
For pretreatment with chloroethylclonidine (CEC), aliquots of membranes were incubated for 30 min at 37°C with 10 fJM CEC in assay buffer (Tris HCI 50 mM, pH 7.5). The reaction was stopped by dilution with ice-cold buffer, followed by three successive 15 min centrifugations at 50,000 g to wash the membranes extensively and completely remove any remaining unbound drug.
[3Hj-prazosin binding studies
Binding of (3H)-prazosin was measured in aliquots of diluted membranes incubated in 50 mM Tris buffer (pH 7.5) with (3H)-prazosin (0.2 nM) and in the absence or presence of 17-20 concentrations of the indicated agents. The incubation volume was 1 mi (approximately 250 fJg protein/tube), but displacement experiments with CEC-treated membranes were carried out in a final volume of 2 mi (approximately 500 fJg protein/tube). The assay tubes were incubated for 45 min at 25°C, and then binding reactions were terminated by rapid vacuum filtration using a Brandel cell harvester (M24R) with glass fibre filters (Schleicher and Schuell, No. 30) presoaked in 0.3% polyethylenimine for 5 mino The filters were then washed four times with 4 mi of ice-cold 50 mM Tris-HCI buffer (pH 7.5), and the filter-bound radioactivity was determined by liquid scintillation counting. Nonspecific binding was defined as binding in the presence of 10 fJM phentolamine. Assays were conducted in duplicate.
Proteins were assayed according to the method of Bradford with globulin as standard (Bradford, 1976) .
Data ana/ysis
Competition binding experiments were analysed by the weighted least-squares iterative curve fitting programme, LI-GAND (Munson & Rodbard, 1980) . The data were first fitted to a one-and then a two-site model, and if the residual sums of squares were statistically less for a two-site fit of data than for a one-site fit, as determined by an F-test comparison, then the two-site model was accepted. The experimental results were expressed as means ± s.e.mean for n determinations obtained from different animals. When ANOV A showed significant R,
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R, R2 OH OH OH OCH3 OCH3 OCH3 Figure 1 Chemical structure of boldine, predicentrine and glaucine. differences (P<0.05) the results were further analysed by the Student-Newman Keuls test. P values less than 0.05 were considered significant.
Drugs
S-( + )-Boldine ( Figure 1 ) was isolated from the plant, Peumus boldus in the Departamento de Química de la Universidad de Chile as previously described (Speisky et al., 1991) ; predicentrine ( Figure 1 ) was prepared from boldine by selective 9-0-methylation (Asensio et al., 1993) . The purity of both compounds (> 99%) was confirmed by t.l.c. and spectral methods (mass, n.m.r.). S-( + )-Glaucine ( Figure 1 ) was purchased from Sigma Chem. CO. The following drugs (sources in parentheses) were used: (3H)-prazosin (specific activity 72-78 Ci mmol-1, Amersham, U.K.); WB 4101 hydrochloride (2-(2,6-dimethoxyphenoxyethyl)-aminomethyl-l ,4-benzodioxane), benoxathian hydrochloride, phentolamine mesylate, chloroethylclonidine dihydrochloride (Research Biochemicals Inc, Natick, MA, U.S.A.).
Results
Binding of (3H)-prazosin to rat cerebral cortex was specific, saturable and showed high affinity. Nonlinear regression ana-'--/ Iysis of the saturation data was consisted with the presence of a single population of sites. The derived I(¡and Broax values were 0.11 ±0.02 nM and 132.5±7.2 fmol mg-I protein, respectively (Sallés & Badía, 1994) . Chloroethylclonidine (CEC) has been reported to inactivate selectively the IXIB-subtype (Han et al., 1987a) . Pretreatment of rat cortical membranes with CEC reduced the density of IXI-adrenoceptors labelled with (3H)-prazosin by 70-75% (Sallés & Badía, 1994) without significantly changing the I(¡value for (3H)-prazosin (Kenny et al., 1994) .
The specific binding of 0.2 nM pH)-prazosin to the IXIadrenoceptors was completely inhibited by WB 4101, benoxathian ( Figure 2 ) and by boldine, predicentrine and glaucine ( Figure 3 ). As expected, displacement curves for WB 4101 and benoxathian were shallow, and computerized analysis of these curves revealed the presence of two distinct sites. The proportion of the high affinity sites defined by the two antagonists amounted to approximately 37% of the total specific binding of (3H)-prazosin (Table 1) .
Boldine, predicentrine and glaucine also displayed biphasic curves (Figure 3) , and the LIGAND analysis fitted the data to a two site model. From the two site fits we calculated that approximately 30-40% of the sites had high affinity for these iX1A-Subtypeselectivity 01 boldine and derivatives 1565 compounds (Table 1 ). This praportion of high affinity sites detected with aporphine alkaloids is similar to that obtained for WB 4101 and benoxathian, and corresponds to the pharmacologically defined IX¡A-adrenoceptor.In some experiments (4 out of 11), glaucine inhibited [3H)-prazosin binding monophasically (LIGAND analysis fitted the data to a one site model) with a single pKi value (pK= 6.13 ±0.09, n=4). Displacement affinities (PKi) for the high and low affinity sites for the different compounds as well as the affinity ratio between subtypes (rKljKh)are shown in Table l . Boldine was the most selective agent for IX¡A-adrenoceptorsand was 70 fold more potent at the IX¡A-than at the IX¡B-subtype; predicentrine was 56 fold more potent although there was not a significant difference with respect to boldine; glaucine was only 17 fold more potent. Moreover, in the case of glaucine there is a significant loss of affinity for both IX¡-adrenoceptor subtypes with respect to boldine and predicen trine.
Although the antagonists, WB-41Ol and benoxathian, exhibited higher affinity for IX¡-adrenoceptor subtypes than boldine, they were less selective for the IXIA-adrenoceptorsubtype and they were found to be only 40 and 22 fold more potent, respectively, at the IXIA-than at the IX¡B-subtype.
The effect of CEC pretreatment on inhibition curves for boldine is shown in Figure 4 . CEC has been used because of its alkylating effects, which are selective for IX¡B-adrenoceptors '--" relative to 1X1A-adrenoceptors (Han el al., 1987a) . As in other studies, pretreatment of rat cortical membranes for 30 min at 37°C with 10 tlM CEC produced a significant reduction in the [3H)-prazosin specific binding (the proportion of the remaining sites was 27.6 ± 6.0%, n = 5) compared with the binding of the membranes without CEC pretreatment. Total binding and specific binding at 0.2 nM [3H)-prazosin were 3716 ± 441 d.p.m. and 91.7 ± 1.5% in CEC-untreated membranes, and 1101± 161 d.p.m. and 74±3.8% in CEC-pretreated membranes. Therefore CEC pretreatment inactivated only a proportion of the IX¡-adrenoceptor binding sites labelled with [3H)-prazosin that corresponds to the proportion of IXIBadrenoceptor subtypes determined in the competition experiments in membranes not pretreated with CEe.
The binding of 0.2 nM [3H)-prazosin in CEC-pretreated membranes was monophasically inhibited by boldine ( Figure  4 ) with a Hill slope not significantly different fram unity (nH=0.93±0.08). The pKi value obtained was 7.76±0.09 (n = 5) and was close to the affinity of boldine for the high affinity sites in CEC-untreated membranes (Table 1) .
Discussion
Recently, it was found that IX¡-adrenoceptors constitute a heterogeneous family of receptors, and several subtypes have been identified by use of a variety of techniques: functional studies, radioligand binding and molecular biology. Although differences in protocol and technique have resulted in several classification schemes, the existence of three subtypes is now recognized, Le. IX¡A, IX¡B, and 1X1D-adrenoceptors (for review see Ford el al., 1994; Hieble el al., 1995; Michel el al., 1995) . Initially, two subtypes of IX¡-adrenoceptors (IX¡A and IX lB), were defined on the basis of binding experiments. Binding sites for [3H)-prazosin with high affinity for WB-4101 and phentolamine (Morrow & Creese, 1986) , as well as oxymetazoline (Hanft & Gross, 1989a) , benoxathian (Han el al., 1987b) , 5-methylurapidil (Gross el al., 1988) , and S-e +)-niguldipine (Boer el al., 1989) were designated 1X1A-adrenoceptors, whereas binding sites with low affinity for these ligands were designated IX¡B-adrenoceptors. In addition, the alkylating agent, chlor- oethylclonidine (CEC) has been proposed to inactivate irreversibly aIB-but not alA-adrenoceptors (Han et al., 1987a; Minneman et al., 1988) . Molecular biological techniques have al10wedthe cloning and expression ofthree receptors, i.e., alb (Cotecchia et al., 1988) , ale (Schwinn et al., 1990 )and the a¡d (Lomasney et al., 1991; Perezet al., 1991) . It has been difficult to establish the relationship between pharmacological1y defined and cloned a¡-adrenoceptors, and their classification is still evolving. Until recentIy only the cloned and pharmacological1y defined aIB-adrenoceptors were considered to represent the same molecular entity (Cotecchia et al., 1988; Lomasneyetal., 1991) .CurrentIy,however, thea¡eclone is also considered to be the same receptor as the classical a¡A-adrenoceptor (Ford et al., 1994; Faure et al., 1994; Perez et al., 1994; Pimoule et al., 1995; Blue et al., 1995) . The cloned a¡d-adrenoceptor seems to represent a novel subtype (i.e. the am adrenoceptor). Thus, the new nomenclature of a¡-adrenoceptors with high affinity for prazosin (native and recombinant receptors: alA and a¡., a¡B and a¡b, am and a¡d, respectively) was recentIy acknowledged by IUPHAR (Hieble et al., 1995) .
These receptor subtypes have different tissue distributions, and in the rat cerebral cortex membranes the prazosin-high affinity sites have been demonstrated to be composed of alA and a¡B subtypes (Morrow & Creese, 1986; Hanft & Gross, 1989b; Graziadei et al., 1989; Oshita et al., 1991; Sal1és& Badia, 1994) .
In our study, the competition curves in rat cerebral cortex of the known alA selective antagonists, WB 4101 and benoxathian for [3H)-prazosin binding were shal10w and biphasic and revealed the existence of a¡A-and a¡B-adrenoceptors at a ratio of approximately 37:63%, which is in good agreement with previously published data (Morrow & Creese, 1986; Hanft & Gross, 1989b; Sal1és& Badia, 1994) . The affinity constants at their high and 10w affinity sites are also in accordance with these previous reports.
Like WB 4101 and benoxathian, boldine also bound to [3H)-prazosin high affinity sites in rat cerebral cortex with two different affinities, thus indicating the presence of at least two a¡-adrenoceptor subtypes. Boldine recognized approximately 33% high affinity sites. Since this proportion is similar to the percentage of high affinity sites for WB 4101 and benoxathian, which are the pharmacologically-defined a¡A-adrenoceptors, it is likely that boldine high affinity sites are of the a¡A-subtype. This implies that boldine is a selective a¡Kadrenoceptor agent relative to aIB-adrenoceptors that exhibits a greater selectivity than that of WB 4101 or benoxathian, for boldine is approximately 70 fold alA-selective, whereas the selectivities of WB or benoxathian are 40 fold and 20 fold, respectively. Boldine, may therefore be a useful tool for studying the a¡-adrenoceptor subtypes present in different tissues.
In order to corroborate the selective action of boldine on the a¡A-adrenoceptor subtype, we tested its effect on [3H)_ prazosin binding to rat cerebral cortical membranes pretreated with CEe. In rat cortical membranes, the pharmacological profile of CEC-insensitive sites appeared to be indicative of a¡A-adrenoceptors, since selective antagonists like WB 4101, benoxathian, phentolamine, niguldipine, or 5-methylurapidil, displayed potencies comparable to that obtained with the high affinity sites in competitive studies in normal membranes (Hanft & Gross, 1989b; Hanft et al., 1989; Han & Minneman, 1991; Sallés & Badia, 1994) , and with cloned a¡A-receptors (for review see Michel et al., 1995) . In these experimental conditions, boldine displayed a steep, monophasic competition curve for [3H)-prazosin binding to rat cortical membranes pretreated with CEC with a single pK¡ value which is close to the affinity of boldine for the high affinity sites determined in membranes not pretreated with CEC.
The present results demonstrate the capacity of boldine, an aporphine alkaloid, to discriminate between the two subtypes of a¡-adrenoceptors present in rat cerebral cortex. Functional studies in rat aorta also suggest a subtype selectivity for boldine. Previous results obtained in our laboratory showed that in rat aorta, noradrenaline concentration-response curves in the presence of boldine could not be accounted for by simple competitive antagonism at a single receptor (Schild slopes significantIy lower than unity), and this suggests a heterogeneity of a¡-adrenoceptors in rat aorta that could be differentiated by boldine (Ivorra et al., 1993) . To date, the data on the a¡-adrenoceptor subtypes present in rat aorta are confusing. Although some studies have suggested that the a¡-adrenoceptor population is a homogeneous entity which has been postulated to be either alA (Beckering & Brodde, 1989) , alB (Eltze & Boer, 1992; Testa et al., 1995) , non-a¡A/non-alB (Oriowo & Ruffol0, 1992; Aboud et al., 1993) , am (Ko et al., 1994), or 'predominantIy' am , others have suggested that a number of different subtypes contribute to the contractile response in rat aorta Van der Graaf et al., 1996) . Moreover, Rokosh et al. (1994) and Piascik et al. (1994) reported that they could detect mRNA for the a¡b, a¡e and a¡d adrenoceptors in the rat aorta.
In order to identify some structural feature accounting for the selectivity showed by boldine, we have assayed the effect of glaucine, another aporphine alkaloid structural1y related to boldine, that also exhibited a¡-adrenoceptor antagonistic activity in different tissues (Ivorra et al., 1992; Orallo et al., 1993; . The binding of ¡JH)-prazosin to rat cerebral cortex membranes was inhibited biphasically by glaucine, indicating two different sites. However, glaucine not only exhibited a significant loss of affinity for a¡-adrenoceptors relative to -J boldine, but also a loss of selectivity between a¡A-and a¡B-subtypes since it is only approximately 15 fold a¡A-selective. Moreover, in some competition binding experiments glaucine was unable to discriminate between subtypes probably due to its low selectivity ratio. A non-selective action of glaucine on a¡-adrenoceptors subtypes has previously described in rat vas deferens (Orallo et al., 1993) .
Boldine and glaucine have similar structures: they are aporphine alkaloids with the configuration 8 and with oxygenated substituents at the same positions. The only difference is the degree of methylation of oxygen atoms. Boldine has two free hydroxyl groups at C-2 and C-9, whereas glaucine has all the oxygen atoms methylated (Figure 1) . The results obtained in the present work showed that the methylation of free hydroxyl functions leads to a drastic decrease in binding affinity and selectivity for a¡-adrenoceptor subtypes. In order to study whether one of the hydroxyl groups may be primarily responsible of this loss of activity we have also analysed the effect of predicentrine, which possesses only a free 2-hydroxyl group. The results obtained showed that predicentrine maintains the ability of boldine to discriminate between the alA and a¡B subtypes with a similar potency and selectivity (60 fold selective for .ã ¡K relative to a¡B-adrenoceptors), which suggest that the presence of a free 2-hydroxy function on the (8)-aporphine skeleton significantIy increases the a¡-subtype selectivity shown by these aporphine alkaloids.
In summary the present study shows that the three (8)-aporphine alkaloids tested by us were able to act at a¡-adrenoceptor subtypes with different degrees of affinity and selectivity (boldine =predicen trine > glaucine), thus suggesting that an aporphine structure is responsible for this activity, whereas a defined functional group, namely the 2-hydroxy function, seems to be a critical factor in the ability of these compounds to discriminate between a¡-adrenoceptor subtypes. It is interesting to note that methylation of the hydroxyl group at the 2-position (glaucine) results in a significant loss in potency and selectivity. This kind of compound could be important not only for the development of new selective agents for the a¡-adrenoceptor family, but also a more thorough structure-activity relationship analysis could lead to understanding of the interactions between the ligand and the different a¡-adrenoceptor subtypes.
